Vertex goes small with Mammoth deal
Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.
Boehringer takes a different approach in cystic fibrosis gene therapy
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
Memed seeks partners for bacterial vs viral testing and more
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
Amylyx changes its mind about an early filing
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
How long will the good times roll for medtech?
The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.
Gilead cements its long-acting HIV ambitions
Mid-stage data with lenacapavir in treatment-naive patients justify pushing on; as for combos, Gilead is keeping its options open.
EQRX vows to slash drug prices where others have failed
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
